The ThroLy score was developed and published in 2016 by a group of physicians from Serbia and the United States.[1] As a simple model, it was initially internally validated based on individual clinical and laboratory patient characteristics that identify lymphoma patients at risk for a thromboembolic event. Based on an investigation that was conducted on derivation and validation cohorts, it was determined that the variables independently associated with a risk of thromboembolism in lymphoma patients are: previous venous and/or arterial events; mediastinal involvement; a BMI greater than 30 kg/m2; reduced mobility; extra-nodal localization; neutropenia; and a hemoglobin level less than 100g/L.[1][2]
Patient characteristics
Assigned score
Previous venous thromboembolic event
2
Reduced mobility
1
Previous acute myocardial infarction or stroke
2
Obesity (BMI ≥ 30)
2
Extranodal localization
1
Mediastinal involvement
2
Neutropenia
1
Hemoglobin˂100g/L
1
Risk classification
Based on the risk score, patients with lymphoma can be classified into three different risk groups. [2]
Risk group
ThroLy score
Low risk
0-1
Intermediate risk
2-3
High risk
≥4
Further validations
The ThroLy score considers some particular characteristics of lymphoma patients, such as extranodal localization and mediastinal involvement. In addition to having a strong positive predictive value, the score is not limited to either hospitalized or outpatient settings, and does not require non-routine laboratory analyses. ThroLy score has been validated by multiple studies and entered clinical practice in several medical centers.[3][4][5] However, multiple validation studies are ongoing and the results of additional studies may be needed before it can be fully applicable in clinical practice worldwide; several validation studies have been performed, and several more are ongoing.[6][7][8]
